Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium
- Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) with associated macular edema
- Oral treatment was well tolerated, showed signs of clinical effect and retinal imaging data consistent with reductions in vascular leakage, one of the core pathologies of NPDR
- Reductions in vascular leakage are well-known to precede reductions in Diabetic Retinopathy Severity Scale (DRSS) scores
- The data support initiation of a Phase 2, randomized clinical trial in patients with NPDR to assess reductions in DRSS scores, which Breye Therapeutics is currently preparing for
Copenhagen, Denmark, 9 February 2026 – Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data showcasing the potential of its lead candidate, danegaptide, was presented at the prestigious Angiogenesis, Exudation, and Degeneration 2026 symposium on 7 February 2026.
